Monocarboxylate Transporter‐1 Is Dispensable for Hepatocellular Carcinoma Development
Molecular Carcinogenesis · 2025
DOI: 10.1002/mc.70021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Shaimaa A Gad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Surgery, Pathology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USA. Hauptthemen laut MEDLINE: Monocarboxylic Acid Transporters, Carcinoma, Hepatocellular, Symporters, Liver Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAAA NIH HHS, This study was supported by National Cancer Institute, the Richard A. Perritt Charitable Foundation, and National Institute on Alcohol Abuse and Alcoholism..
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer and the deadliest liver disease. It is imperative to understand the underlying molecular mechanisms involved in the development of HCC. Monocarboxylate transporter‐1 (MCT1) is a proton‐coupled protein that facilitates the bidirectional transport of monocarboxylates, such as lactate and pyruvate, across the plasma membrane to maintain the cellular metabolism and energy supply. MCT1 was found to be upregulated in human HCC specimens, and its inhibition reduced xenograft tumor growth. However, the role of MCT1 in HCC remains to be further investigated using immune‐competent in vivo models. To better understand the role of MCT1 in HCC, we established liver‐specific MCT1 knockout mice. We found that deletion of MCT1 in liver cells did not affect morphology, proliferation, or apoptosis. DEN/CCl4 model, where a single injection of DEN is followed by repeated injections of CCl4, was used to induce HCC in mice. Intriguingly, we found that liver‐specific knockout of MCT1 was not sufficient to reduce the size or count of DEN/CCl4‐induced liver tumors. In addition, we used immunohistochemical staining to evaluate the expression of Ki67, collagen A1, and myeloperoxidase, and we found that MCT1 knockout was not able to hinder the proliferation, fibrosis, and inflammation in the DEN/CCl4‐induced HCC tumors. In conclusion, MCT1 is dispensable for HCC development, and its deletion was insufficient to alleviate the phenotypic repercussions of HCC tumors in the DEN/CCl4‐induced HCC model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Surgery, Pathology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USA.
- Departments of Cancer Biology, Pathology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USA.
- Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Center, Egypt.
- Department of Pathology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USA.
ORCID-Profile: Bryan Bridgeman, Wei Qiu
Förderung
- NCI NIH HHS
- NIAAA NIH HHS
- This study was supported by National Cancer Institute, the Richard A. Perritt Charitable Foundation, and National Institute on Alcohol Abuse and Alcoholism.
- National Cancer Institute
Zitieren
APA
Gad, S. A., Bridgeman, B., Boedeker, K., Ding, X., & Qiu, W. (2025). Monocarboxylate Transporter‐1 Is Dispensable for Hepatocellular Carcinoma Development. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70021
Vancouver
Gad SA, Bridgeman B, Boedeker K, Ding X, Qiu W. Monocarboxylate Transporter‐1 Is Dispensable for Hepatocellular Carcinoma Development. Molecular Carcinogenesis. 2025. doi:10.1002/mc.70021
BibTeX
@article{Gad2025,
author = {Gad, Shaimaa A and Bridgeman, Bryan and Boedeker, Kyle and Ding, Xianzhong and Qiu, Wei},
title = {Monocarboxylate Transporter‐1 Is Dispensable for Hepatocellular Carcinoma Development},
journal = {Molecular Carcinogenesis},
year = {2025},
doi = {10.1002/mc.70021}
}
EUVIMED